Estudo randomizado | Ibandronato oral adjuvante não melhora os desfechos em mulheres na pós-menopausa com câncer de mama positivos para receptor de estrogênio.
22 Ago, 2022 | 14:34hDaily Oral Ibandronate With Adjuvant Endocrine Therapy in Postmenopausal Women With Estrogen Receptor–Positive Breast Cancer (BOOG 2006-04): Randomized Phase III TEAM-IIB Trial – Journal of Clinical Oncology (link para o resumo – $ para o texto completo)
Comentário: Adjuvant Ibandronate Not Beneficial for ER+ Breast Cancer – Cancer Therapy Advisor
Comentário no Twitter
New phase 3 trial of adjuvant bisphosphonates for ER+ eBC published on @JCO_ASCO.
1,116 patients randomized to ET +/- 3 years of ibandronate. No DFS benefit (HR 0.97, p=0.81). Eleven patients in the ibandronate arm developed osteonecrosis of the jaw.https://t.co/CxhZcTNLhU— Paolo Tarantino (@PTarantinoMD) April 21, 2022